Company / PP&E (Net)
Kymera Therapeutics, Inc. PP&E (Net) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$43.2M
FY2025
5-year range
$11.9M / $50.5M
FY2021-FY2025
Trend
-14.4%
vs FY2024
Sector context
#65 of 193
Health Care
What the data says
At $43M, Kymera Therapeutics, Inc.'s pp&e (net) ranks #65 of 193 in the Health Care sector. Declined from $48M to $43M over the past 2 years.
Based on SEC 10-K filings.
$43M in FY2025 with a 5-year CAGR of +31.8%.
Declined from $48M to $43M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +47.9%
- 5-Year CAGR
- +31.8%
- 10-Year CAGR
- -
Sector benchmark
#65 of 193 in Health CareTop 34% of 193This company $43.2M Sector average $777.6M
▼
-94.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +31.8%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 14.4% year-over-year.
- Ranks #65 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $43.2M | -14.4% |
| FY2024 | $50.5M | +4.8% |
| FY2023 | $48.1M | +261.0% |
| FY2022 | $13.3M | +12.2% |
| FY2021 | $11.9M | +9.6% |
| FY2020 | $10.8M | +185.7% |
| FY2019 | $3.8M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026